Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Genetics to Announce Financial Results for the Second Quarter of Fiscal Year 2014 on Tuesday February 4, 2014

Globe Newswire January 23, 2014

Myriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium

Globe Newswire January 23, 2014

Myriad Genetics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Globe Newswire January 7, 2014

TrendingWallStreet.com Begins to Trend MYGN, KO, MMTIF, and BORN

Accesswire December 31, 2013

Myriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study

Globe Newswire December 14, 2013

Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent

Globe Newswire December 12, 2013

Myriad Genetics Announces Cancer Research Collaboration With Janssen

Globe Newswire December 9, 2013

Myriad Genetics Announces Upcoming Investor Event

Globe Newswire December 5, 2013

Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer

Globe Newswire December 4, 2013

TrendingWallStreet.com Begins Volume Coverage on MYGN, FNMA, ABX, and GALE

Accesswire December 3, 2013

Invitae Files Suit Against Myriad Genetics

Business Wire December 2, 2013

Myriad Genetics Announces Second HRD Collaboration

Globe Newswire November 20, 2013

Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test

Globe Newswire November 12, 2013

Myriad Genetics to Present at the 2013 Credit Suisse Annual Healthcare Conference

Globe Newswire November 8, 2013

MYGN, NPSP, DRTX and AMRI added to NASDAQ Active Stock Watch List at GSR

Accesswire November 6, 2013

Myriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists

Globe Newswire October 29, 2013

Myriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study

Globe Newswire October 28, 2013

Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study

Globe Newswire October 24, 2013

Myriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013

Globe Newswire October 23, 2013

Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study

Globe Newswire October 14, 2013
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested